Featured Press Releases

Tentarix Biotherapeutics announces appointment of Andrew D. Kidd, MD, CFA, as CEO

Tentarix Biotherapeutics announces appointment of Andrew D. Kidd, MD, CFA, as CEO

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

  • 03 Sep 2025

Eisai Co., Ltd. and Biogen Inc. announced that Eisai has initiated the rolling submission of the...

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

Hoth Therapeutics teams up with OnTargetx R&D to further research for the cancer-fighting HT-KIT therapeutic

Hoth Therapeutics teams up with OnTargetx R&D to further research for the cancer-fighting HT-KIT therapeutic

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

To strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities, Precision AQ expands its senior leadership team

  • Precision AQ
  • 17 Feb 2026
New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

New ECCO data demonstrate that subcutaneous infliximab (Remsima™ SC) recaptures and maintains disease control following a drug holiday

  • Celltrion
  • 16 Feb 2026
Breakthrough in Zika Virus Drug Discovery Reported by IRBM

Breakthrough in Zika Virus Drug Discovery Reported by IRBM

  • IRBM
  • 14 Feb 2026
A Breakthrough Study Confirms HYD LLC

A Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression.

  • HYD LLC
  • 13 Feb 2026
FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.